Recently, expression levels of P2Y6 receptor in PD patients younger than 80 years were higher than healthy controls and multiple system atrophy (MSA) patients and P2Y6 receptor could thereby be a potential clinical biomarker of PD. This evidence concerns the gene P2RY6 and multiple system atrophy.